PIERIS PHARMACEUTICALS, INC. License Agreements
7 Contracts & Agreements
- Exclusive Product License Agreement, dated April 24, 2021, by and among Pieris Pharmaceuticals, Inc., Pieris Pharmaceuticals GmbH and BP Asset XII, Inc (Filed With SEC on August 5, 2021)
- Amendment No. 1, dated March 29, 2021, to the Non-Exclusive Anticalin Platform License Agreement, dated May 2, 2017, by and between Pieris Pharmaceuticals, Inc. and AstraZeneca AB (Filed With SEC on May 17, 2021)
- NON-EXCLUSIVE ANTICALIN® PLATFORM TECHNOLOGY LICENSE AGREEMENT (Filed With SEC on March 30, 2017)
- AMENDMENT NO. 1 TO DEFINITIVE LICENSE AND TRANSFER AGREEMENT (Filed With SEC on March 30, 2017)
- CONFIDENTIAL TREATMENT REQUESTED DEFINITIVE LICENSE ANDTRANSFER AGREEMENT (Filed With SEC on August 11, 2016)
- CONFIDENTIAL TREATMENT REQUESTED LICENSE AND TRANSFER AGREEMENT (Filed With SEC on May 12, 2016)
- CONFIDENTIAL TREATMENT REQUESTED SIDE AGREEMENT to theCollaboration and License Agreement between Sanofi, Sanofi-Pasteur and Pieris (Filed With SEC on February 17, 2015)
